Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for ICANS Prevention in Large B-cell Lymphoma
NCT04205838Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2020
- Primary completion
- Feb 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of anakinra in immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Number of patients who met the eligibility criteria to receive and did receive anakinra at 12 months. Started Mar 2020; status: terminated.
02
Drugs
anakinra
03
Conditions
immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT04205838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205838.